CNS Cancers

Vaccine-Chemotherapy Combination in Glioblastoma

Despite highly aggressive therapy that includes maximal tumor resection, high-dose radiation, and temozolomide chemotherapy...

Lung Cancer

Sacituzumab Govitecan in Metastatic NSCLC

As reported by Rebecca Suk Heist, MD, MPH, of Massachusetts General Hospital, and colleagues in the Journal of Clinical Oncology, the antibody-drug...

Cost of Care
Symptom Management

Cost of Hospitalization for Cancer-Related Neutropenia or Fever

In a study of 2012 data, Eric Tai, MD, of the Division of Cancer Prevention and Control, Centers for Disease Control and Prevention...


Advertisement

More Top Stories

Kidney Cancer

Bernard J. Escudier, MD, and Sumanta K. Pal, MD, on RCC: Trial Results on Sunitinib

ASCO Resource to Help Your Patients Quit Tobacco

ASCO’s patient booklet Stopping Tobacco Use After a Cancer Diagnosis offers people with cancer and their caregivers information on why and how to quit tobacco use. With information on available treatments and resources, this booklet gives patients the practical tools to work with their health-care...

Advertisement

FDA Approves Inotuzumab Ozogamicin for Relapsed or Refractory B-Cell Precursor ALL

On August 17, 2017, the U.S. Food and Drug Administration (FDA) approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). INO-VATE ALL The approval was based on data from INO-VATE ALL, a randomized (1:1), ...

Colorectal Cancer

Temidayo Fadelu, MD, on Colon Cancer: Results From the CALGB 89803 Trial

Thyroid Cancer

Are Thyroid Cancer Incidence and Mortality Rates Truly Increasing in the United States?

THYROID CANCER diagnoses are increasing at a rate faster than any other malignancy in the United States. In 2017, there will be 56,870 new cases, accounting for 3.4% of all cancers, and 2,010 people will die of thyroid cancer.1 This represents a more than 200% increase in incidence since the...

Don’t Miss Your Chance to Participate in the 2017 ASCO Practice Census

There is less than 1 month left to participate in this year’s ASCO Practice Census— the only annual survey of the entire U.S. oncology practice community that aims to identify changes in cancer care and oncology practice over time. It is crucial that practices in all settings across the United...

FDA Accepts sBLA and Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell Lymphoma

On August 16, the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL). The sBLA and its acceptance is based on data from the phase III...

Gynecologic Cancers

Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the SOLO2 Trial

Syed Abutalib, MD, Appointed to Education Committee for ASBMT

THE CANCER TREATMENT CENTERS OF AMERICA issued congratulations to Syed Abutalib, MD, in July for being appointed to the Education Committee for the American Society for Blood and Marrow Transplantation (ASBMT). Dr. Abutalib is Assistant Director, Stem Cell Transplant & Cell Therapy Program at ...

Advertisement

Plasma Epstein-Barr Virus DNA Screening for Nasopharyngeal Cancer

In a Hong Kong study reported in The New England Journal of Medicine, Chan et al found that screening for circulating cell-free Epstein-Barr virus (EBV) DNA is useful in detecting nasopharyngeal carcinoma in asymptomatic individuals. Study Details In the study, 20,174 participants underwent...